Gamma-aminobutyric acid type A receptor alpha-3 beta gamma (α3-GABAAR)

The Gamma-aminobutyric acid type A receptor alpha-3 beta gamma (GABAA receptor α3βγ) is a heteropentameric ligand-gated ion channel that mediates fast inhibitory neurotransmission in the mammalian central nervous system. It is typically composed of two α3 subunits, two β subunits, and one γ subunit, with the benzodiazepine binding site located at the extracellular interface between the α3 and γ subunits. This receptor subtype is prominently expressed in the reticular nucleus of the thalamus, the amygdala, and the dorsal horn of the spinal cord, where it plays a key role in modulating anxiety, muscle tone, and sensory processing, including pain. Pharmacological targeting of α3-containing receptors is a major area of interest for developing "next-generation" anxiolytics and analgesics that lack the profound sedative and cognitive-impairing effects associated with α1-selective or non-selective GABAergic drugs. Positive allosteric modulators selective for the α3 subunit have shown promise in preclinical models for treating neuropathic pain and generalized anxiety disorder without the typical benzodiazepine-related side effects like ataxia and sedation. Furthermore, alterations in the expression of the α3 subunit have been implicated in the pathogenesis of epilepsy, schizophrenia, and certain malignancies, suggesting its potential as both a therapeutic target and a diagnostic biomarker.

Other names

GABRA3-containing GABAA receptorAlpha-3 subunit-containing GABA-A receptorGABAA receptor alpha-3 beta-gammaGABAA receptor α3βγ

Positive allosteric modulation (PAM) at the benzodiazepine binding site (located at the α3/γ interface), which enhances the inhibitory effect of GABA by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization.